I have a PhD from the University of Nottingham in designing polymeric nanoparticles for tumour targeting, with my first degree in Pharmacy from India. I joined AstraZeneca in 2008, working on the formulation of clinical products for inhalation.

In 2010, I moved into the Pharmaceutical Development team and worked extensively in the field of advanced nanomedicines and new modalities for oncology therapeutics.

I progressed to the role of Associate Principal Scientist in 2013 and became involved in driving innovative science and implementing clinical development strategies applied to nanomedicines and nucleic acid-based therapeutics.

I moved to Cambridge in 2017 as a team leader of the Advanced Drug Delivery team and established a team of multidisciplinary scientists from leading drug delivery groups with expertise in drug delivery sciences and cell biology.
 

My passion lies in internal and external collaboration, to help identify and implement novel product opportunities that strengthen our pipeline, achieve scientific leadership and ultimately make a meaningful difference to patient health.

Sanya Puri Associate Director, Advanced Drug Delivery, Pharmaceutical Sciences, R&D

CURRENT ROLE

Associate Director, Advanced Drug Delivery, Pharmaceutical Sciences, R&D

2018

Established Cambridge nanomedicine capability with multidisciplinary team of Advanced Drug Delivery scientists

2013

Helped select and establish external collaborations with Moderna and Ionis to advance nucleic-acid based therapeutics

2008

Explored external opportunities, securing Innovative UK grant worth £1M

  Featured publications

Differential uptake, kinetics and mechanisms of intracellular trafficking of next-generation antisense oligonucleotides across human cancer cell lines.

Linnane E, Davey P, Zhang P, Puri S,  Edbrooke M, Chiarparin E, Revenko AS, Macleod AR, Norman JC, Ross SJ. Nucleic Acids Research (2019). 9: 4375-4392. Publication link.

CD44 targeted delivery of siRNA by using HA-decorated nanotechnologies for KRAS silencing in cancer treatment.

Tirella A, Kloc-Muniak K, Good L, Ridden J, Ashford M, Purie S, Tirelli N. International Journal of Pharmaceutics (2019), 561: 114-123. Publication link.

Serum Nuclease susceptibility of mRNA cargo in condensed Polyplexes.

Yen A, Cheng Y, Sylvestre M, Gustafson HH, Ouri S, Pun SH., Mol. Pharmaceutics (2018), 15:(6), 2268–2276 Publication link.

Evaluation of dynamic contrast-enhanced MRI biomarkers for stratified cancer medicine: How do permeability and perfusion vary between human tumours?

Little RA, Barjat H, Hare JI, Jenner M, Watson Y, Cheung S, Holliday K, Zhang W, O’Connor JBP, Barry ST, Puri S, Parker GJM, Waterton JC. Magn Reson Imaging (2018), 46:98-105. Publication link.

Chitosan/Hyaluronic Acid Nanoparticles: Rational Design Revisited for RNA Delivery

Lallana E, Tirella A, Puri S, Ashford A, Tirelli N, Mol Pharm. (2017), 14(7):2422-2436. Publication link.

Challenges and strategies in anti-cancer nanomedicine development: an industry perspective.

Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST. Adv. Drug Deliv Rev (2016) 108, 25-38. Publication link.